Healix® is Now a National Provider of Cuvitru® [Immune Globulin Subcutaneous (Human)] 20%


SUGAR LAND, TX (March 20, 2017) – Healix has been selected among an exclusive number of distributers to become a national provider of Cuvitru [Immune Globulin Subcutaneous (Human)] 20%.

Immunologists who partner with Healix receive a collection of clinical and business services created to help in-source patient care and internalize all revenue from SCIg patients. Service offerings include a customizable range of pharmaceutical dispensing, clinical support, and revenue cycle services to optimize physicians’ resources and improve efficiency.

All medications and services provided by Healix’s state-of-the-art pharmacy facility enable physicians to retain patients and provide services exclusively through their practice. The pharmacy is licensed in 37 states to provide products including Cuvitru®, Gammagard Liquid®, Gamunex®-C, Hizentra®, and HyQvia® to meet clients’ SCIg needs.

For more information, please contact Healix at 1.866.654.2451 or [email protected].


As the national leader in physician office infusion center management, Healix works with physicians by providing clinical staffing, revenue cycle management, customized infusion solutions, and more. We work to help our physician clients provide enhanced patient care and a solution for previously undercompensated cognitive services. www.healix.net

View All

Phase II and Phase III Studies

Healix regularly and actively supports Phase II and Phase III clinical trials in each of our specialty areas, including active studies in therapies for COVID-19, Multiple Sclerosis and Intestinal Bowel Disease.

For information on partnering with Healix on a study, please contact us.